• Exploring the possibility of providing incentives to private industry to invest in disease-modifying interventions by convening a panel of experts from private industry to help determine the nature of possible incentives that would accelerate discovery. These may include tax reform or incentives to drive greater investment, patent law reform to include pharmaceutical incentives, and enhanced market exclusivity.
The council is scheduled to meet again on April 17, 2012. A final draft is expected to be released in late spring 2012.